Skip to main content
An official website of the United States government

Trametinib Dimethyl Sulfoxide

Placeholder slot
 (truh-MEH-tih-nib dy-MEH-thul sul-FOK-side)

This page contains brief information about trametinib dimethyl sulfoxide and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.

US Brand Name(s)
FDA Approved

FDA label information for this drug is available at DailyMed.

Use in Cancer

Trametinib dimethyl sulfoxide is approved to be used alone or with dabrafenib mesylate to treat patients whose cancer has a certain mutation in the BRAF gene, including:

  • Anaplastic thyroid cancer that has spread and cannot be treated with local therapy. It is used with dabrafenib mesylate.
  • Glioma that is low grade in children aged 1 year and older who require systemic therapy. It is used with dabrafenib mesylate.
  • Melanoma. It is used:
    • With dabrafenib mesylate in patients who have had surgery to remove cancer that has spread to the lymph nodes.
    • Alone or with dabrafenib mesylate in patients whose cancer cannot be removed by surgery or has spread to other parts of the body.
  • Non-small cell lung cancer that has spread to other parts of the body. It is used with dabrafenib mesylate.
  • Solid tumors. It is used with dabrafenib mesylate in adults and children aged 6 years and older whose tumors cannot be removed by surgery or have spread to other parts of the body and have gotten worse after other treatment and cannot be treated with other therapies.¹

¹This use is approved under FDA’s Accelerated Approval Program. As a condition of approval, a confirmatory trial(s) must show that trametinib dimethyl sulfoxide provides a clinical benefit in these patients.

Trametinib dimethyl sulfoxide is also being studied in the treatment of other types of cancer.

More About Trametinib Dimethyl Sulfoxide

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

MedlinePlus Information on Trametinib Dimethyl Sulfoxide - A lay language summary of important information about this drug that may include the following:

  • warnings about this drug,
  • what this drug is used for and how it is used,
  • what you should tell your doctor before using this drug,
  • what you should know about this drug before using it,
  • other drugs that may interact with this drug, and
  • possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

Research Results and Related Resources

Drug Combination Shows Promise for Rhabdomyosarcoma, but Can It Get to Clinical Trials?

Dabrafenib–Trametinib Combination Approved for Solid Tumors with BRAF Mutations

Androgen Receptor May Explain Sex Differences in Melanoma Treatment Response

For Some Kids with Brain Cancer, Targeted Therapy Is Better than Chemo

Targeted Cancer Therapies

Trametinib Is a New Treatment Option for Rare Form of Ovarian Cancer

Immunotherapy Combination Most Effective as Initial Treatment for BRAF+ Melanoma

Clinical Trials Accepting Patients

Find Clinical Trials for Trametinib Dimethyl Sulfoxide - Check for trials from NCI's list of cancer clinical trials now accepting patients.

  • Posted:
  • Updated: